Retinal specialists knew that this would be on the cards at some point, but managing proliferative diabetic retinopathy (PDR) with regular intravitreal injections is not standard practice in the UK. This is perhaps due to cost, service pressures, or the fear of non-attendance or service-initiated re-schedulings causing re-proliferation at the retina and subsequent complications such… Read More
New anti-VEGF agent for wet macular degeneration
Brolucizumab, a novel anti-VEGF agent for wet macular degeneration, has reported promising results in phase II clinical trials, and Phase III trials are underway. What is interesting is that many patients appear to be maintained on one of these injections every 12 weeks. More data will doubtless become available from larger studies in due course.… Read More
